847559-67-5Relevant articles and documents
Combining hit identification strategies: Fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone
Brough, Paul A.,Barril, Xavier,Borgognoni, Jenifer,Chene, Patrick,Davies, Nicholas G. M.,Davis, Ben,Drysdale, Martin J.,Dymock, Brian,Eccles, Suzanne A.,Garcia-Echeverria, Carlos,Fromont, Christophe,Hayes, Angela,Hubbard, Roderick E.,Jordan, Allan M.,Jensen, Michael Rugaard,Massey, Andrew,Merrett, Angela,Padfield, Antony,Parsons, Rachel,Radimerski, Thomas,Raynaud, Florence I.,Robertson, Alan,Roughley, Stephen D.,Schoepfer, Joseph,Simmonite, Heather,Sharp, Swee Y.,Surgenor, Allan,Valenti, Melanie,Walls, Steven,Webb, Paul,Wood, Mike,Workman, Paul,Wright, Lisa
supporting information; experimental part, p. 4794 - 4809 (2010/03/01)
Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential molecular therapeutic agents for the treatment of cancer. Here we describe novel 2-aminothieno[2,3-d]pyrimidine ATP competitive Hsp90 inhibitors, which were designed
PYRIMIDOTHIOPHENE COMPOUNDS FOR USE AS HSP90 INHIBITORS
-
Page/Page column 16, (2008/06/13)
Certain specific compounds of formula (I) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment ofinter alia, cancer: formula (I) wherein R2 is a group of formula -(Ar1)m-(Alk1)P
